First molecular therapeutic for Angelman syndrome to advance into clinical trials
The scientists from Texas A&M have developed GTX-102, a novel…
The scientists from Texas A&M have developed GTX-102, a novel therapeutic candidate to target Angelman syndrome by reactivating expression of deficient protein.